Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)
Sponsor
Beijing Anzhen Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05246722
Collaborator
(none)
15,000
46
Study Details
Study Description
Brief Summary
A registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational [Patient Registry]
Anticipated Enrollment
:
15000 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease
Anticipated Study Start Date
:
Feb 1, 2022
Anticipated Primary Completion Date
:
Dec 1, 2024
Anticipated Study Completion Date
:
Dec 1, 2025
Outcome Measures
Primary Outcome Measures
- main adverse cardiovascular and cerebrovascular events (MACCE) [up to 3 years]
MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization
Secondary Outcome Measures
- Adverse drug reaction [up to 3 years]
Adverse drug reaction will be defined as any adverse reactions in the patients
Eligibility Criteria
Criteria
Ages Eligible for Study:
65 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Informed consent has been signed
-
Patients diagnosed in our hospital with coronary heart disease
-
Age ≥65 years
Exclusion Criteria:
-
Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.
-
Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Beijing Anzhen Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Lin Yang,
Director of pharmacy department of Beijing Anzhen Hospital,
Beijing Anzhen Hospital
ClinicalTrials.gov Identifier:
NCT05246722
Other Study ID Numbers:
- ANZHEN HOSPITOL-LY-03
First Posted:
Feb 18, 2022
Last Update Posted:
Feb 18, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: